Literature DB >> 24554654

Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity.

Pinghuang Liu1, Latonya D Williams, Xiaoying Shen, Mattia Bonsignori, Nathan A Vandergrift, R Glenn Overman, M Anthony Moody, Hua-Xin Liao, Daniel J Stieh, Kerrie L McCotter, Audrey L French, Thomas J Hope, Robin Shattock, Barton F Haynes, Georgia D Tomaras.   

Abstract

Antibody capacity to recognize infectious virus is a prerequisite of many antiviral functions. We determined the infectious virion capture index (IVCI) of different antibody specificities. Whereas broadly neutralizing antibodies (bNAbs), except for an MPER bNAb, selectively captured infectious virions, non-bNAbs and mucosal human immunodeficiency virus type 1 (HIV-1)-positive IgG captured subsets of both infectious and noninfectious virions. Infectious virion capture was additive with a mixture of antibodies, providing proof of concept for vaccine-induced antibodies that together have improved capacity to recognize infectious virions.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24554654      PMCID： PMC3993833          DOI： 10.1128/JVI.03765-13

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  30 in total

Review 1.  Strategies for eliciting HIV-1 inhibitory antibodies.

Authors:  Georgia D Tomaras; Barton F Haynes
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

2.  Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

Authors:  J R Mascola; M K Louder; T C VanCott; C V Sapan; J S Lambert; L R Muenz; B Bunow; D L Birx; M L Robb
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.

Authors:  Pinghuang Liu; Nicole L Yates; Xiaoying Shen; Mattia Bonsignori; M Anthony Moody; Hua-Xin Liao; Youyi Fong; S Munir Alam; R Glenn Overman; Thomas Denny; Guido Ferrari; Christina Ochsenbauer; John C Kappes; Victoria R Polonis; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; David C Montefiori; Peter Gilbert; Nelson L Michael; Jerome H Kim; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

4.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.

Authors:  S Johnson; C Oliver; G A Prince; V G Hemming; D S Pfarr; S C Wang; M Dormitzer; J O'Grady; S Koenig; J K Tamura; R Woods; G Bansal; D Couchenour; E Tsao; W C Hall; J F Young
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

5.  Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.

Authors:  Pascal Poignard; Maxime Moulard; Edwin Golez; Veronique Vivona; Michael Franti; Sara Venturini; Meng Wang; Paul W H I Parren; Dennis R Burton
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

7.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.

Authors:  Hua-Xin Liao; Mattia Bonsignori; S Munir Alam; Jason S McLellan; Georgia D Tomaras; M Anthony Moody; Daniel M Kozink; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Pinghuang Liu; Xiaozhi Lu; Robert J Parks; David C Montefiori; Guido Ferrari; Justin Pollara; Mangala Rao; Kristina K Peachman; Sampa Santra; Norman L Letvin; Nicos Karasavvas; Zhi-Yong Yang; Kaifan Dai; Marie Pancera; Jason Gorman; Kevin Wiehe; Nathan I Nicely; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Faruk Sinangil; Jerome H Kim; Nelson L Michael; Thomas B Kepler; Peter D Kwong; John R Mascola; Gary J Nabel; Abraham Pinter; Susan Zolla-Pazner; Barton F Haynes
Journal:  Immunity       Date:  2013-01-11       Impact factor: 31.745

8.  Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation.

Authors:  Rajesh P Ringe; Rogier W Sanders; Anila Yasmeen; Helen J Kim; Jeong Hyun Lee; Albert Cupo; Jacob Korzun; Ronald Derking; Thijs van Montfort; Jean-Philippe Julien; Ian A Wilson; Per Johan Klasse; Andrew B Ward; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

9.  Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41.

Authors:  Jia Chen; Gary Frey; Hanqin Peng; Sophia Rits-Volloch; Jetta Garrity; Michael S Seaman; Bing Chen
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

10.  Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.

Authors:  M K Gorny; J P Moore; A J Conley; S Karwowska; J Sodroski; C Williams; S Burda; L J Boots; S Zolla-Pazner
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103
View more
  33 in total

1.  Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.

Authors:  Randi B Gombos; Dror Kolodkin-Gal; Leila Eslamizar; Joshua O Owuor; Emanuele Mazzola; Ana M Gonzalez; Birgit Korioth-Schmitz; Rebecca S Gelman; David C Montefiori; Barton F Haynes; Joern E Schmitz
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

2.  A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities.

Authors:  Jeffrey R Schneider; Xiaoying Shen; Chiara Orlandi; Tinashe Nyanhete; Sheetal Sawant; Ann M Carias; Archer D Smith; Neil L Kelleher; Ronald S Veazey; George K Lewis; Georgia D Tomaras; Thomas J Hope
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

3.  Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.

Authors:  LaTonya D Williams; Gilad Ofek; Sebastian Schätzle; Jonathan R McDaniel; Xiaozhi Lu; Nathan I Nicely; Liming Wu; Caleb S Lougheed; Todd Bradley; Mark K Louder; Krisha McKee; Robert T Bailer; Sijy O'Dell; Ivelin S Georgiev; Michael S Seaman; Robert J Parks; Dawn J Marshall; Kara Anasti; Guang Yang; Xiaoyan Nie; Nancy L Tumba; Kevin Wiehe; Kshitij Wagh; Bette Korber; Thomas B Kepler; S Munir Alam; Lynn Morris; Gift Kamanga; Myron S Cohen; Mattia Bonsignori; Shi-Mao Xia; David C Montefiori; Garnett Kelsoe; Feng Gao; John R Mascola; M Anthony Moody; Kevin O Saunders; Hua-Xin Liao; Georgia D Tomaras; George Georgiou; Barton F Haynes
Journal:  Sci Immunol       Date:  2017-01-27

Review 4.  Complex immune correlates of protection in HIV-1 vaccine efficacy trials.

Authors:  Georgia D Tomaras; Stanley A Plotkin
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 5.  HIV antibodies for treatment of HIV infection.

Authors:  David M Margolis; Richard A Koup; Guido Ferrari
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 6.  Progress in HIV-1 vaccine development.

Authors:  Barton F Haynes; M Anthony Moody; Munir Alam; Mattia Bonsignori; Laurent Verkoczy; Guido Ferrari; Feng Gao; Georgia D Tomaras; Hua-Xin Liao; Garnett Kelsoe
Journal:  J Allergy Clin Immunol       Date:  2014-06-26       Impact factor: 10.793

7.  HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein.

Authors:  Jia Chen; James M Kovacs; Hanqin Peng; Sophia Rits-Volloch; Jianming Lu; Donghyun Park; Elise Zablowsky; Michael S Seaman; Bing Chen
Journal:  Science       Date:  2015-06-25       Impact factor: 47.728

Review 8.  Molecular determinants of the ratio of inert to infectious virus particles.

Authors:  P J Klasse
Journal:  Prog Mol Biol Transl Sci       Date:  2014-12-01       Impact factor: 3.622

9.  HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.

Authors:  Justin Pollara; Mattia Bonsignori; M Anthony Moody; Pinghuang Liu; S Munir Alam; Kwan-Ki Hwang; Thaddeus C Gurley; Daniel M Kozink; Lawrence C Armand; Dawn J Marshall; John F Whitesides; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Merlin L Robb; Robert J O'Connell; Jerome H Kim; Nelson L Michael; David C Montefiori; Georgia D Tomaras; Hua-Xin Liao; Barton F Haynes; Guido Ferrari
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

10.  Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.

Authors:  P J Klasse
Journal:  Adv Biol       Date:  2014-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.